How does AstraZeneca ensure drug safety?

AstraZeneca employs a comprehensive approach to ensure drug safety throughout the entire life cycle of its products. The process begins with rigorous preclinical testing, which involves laboratory and animal studies to assess the safety and efficacy of new compounds before they are tested in humans. Once a drug progresses to clinical trials, AstraZeneca conducts extensive Phase I, II, and III studies to evaluate safety and effectiveness in a controlled environment with volunteer participants. During these trials, adverse events are carefully monitored and reported to regulatory authorities. AstraZeneca adheres to stringent regulatory requirements set by organizations like the U.S. Food and Drug Administration and the European Medicines Agency, which mandate a thorough evaluation of safety data before approval can be granted. Post-marketing surveillance, also known as pharmacovigilance, is another key component of AstraZeneca's safety measures. After a drug is approved and made available to the public, AstraZeneca continues to monitor its safety in the broader population. This involves collecting and analyzing data on adverse events reported by healthcare providers and patients. By implementing risk management strategies, conducting safety reviews, and engaging with healthcare professionals, AstraZeneca strives to ensure the continuous safety and well-being of those who use its medications. For more detailed information, visiting the official AstraZeneca website may be helpful.